

Ref. No. JPL/CS/1899/2023

Date: 7th February, 2023.

To
BSE Ltd.
P.J. Towers, Dalal Street,
Mumbai - 400 001.

Sub.: Outcome of Board Meeting held today, i.e. 07th February, 2023- Standalone Unaudited Financial Results for the quarter and nine months ended on 31st December, 2022.

Reg.: Regulation 30(2) & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.

Dear Sir,

1. The Standalone Unaudited Financial Results for the quarter and nine months ended on 31st December, 2022 have been approved and adopted by the Board, on the recommendation of Audit Committee, vide their respective meetings held on even date. The same has been attached herewith in the format required under Regulation 33(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.
2. The Limited Audit Review Report of Auditors of the Company, on the standalone Unaudited Financial Results for the quarter ended on 31st December, 2022, is also attached.

Kindly take on record the above and acknowledge.

Thanking you,

Yours faithfully,
For Jenburkt Pharmaceuticals Limited,



ASHISH R. SHAH
Company Secretary and Compliance officer.

Encl.: As stated above.

Statement of Standalone Unaudited Financial Results for the Quarter and nine months ended on 31st December, 2022


(Rs. in Lacs other than EPS)

	Particulars	Quarter Ended			Year to Date		Year Ended
		31-12-2022	30-09-2022	31-12-2021	31-12-2022	31-12-2021	31-03-2022
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operations	3456.58	3585.22	3300.21	10154.99	9569.03	12398.04
II	Other Income	146.37	126.14	128.50	386.77	367.05	494.87
III	Total income (I + II)	3602.95	3711.36	3428.71	10541.76	9936.08	12892.91
IV	Expenses						
	(a) Cost of Materials Consumed	291.95	277.11	344.35	849.09	887.70	1173.86
	(b) Purchase of Stock-in-trade	562.39	614.78	622.98	1696.42	1659.42	2198.08
	(c) Changes in inventories of Finished Goods, Stock-in-trade and WIP	-43.84	-27.76	-162.79	-156.48	-137.76	-228.47
	(d) Employee benefit expenses	1044.76	1007.70	962.37	2968.84	2738.55	3649.09
	(e) Finance Costs	10.31	9.35	10.09	28.32	31.32	43.45
	(f) Depreciation and Amortisation Expense	58.44	54.49	47.29	166.47	136.05	189.87
	(g) Other expenses	903.24	851.81	835.94	2510.21	2160.89	2879.94
	Total Expenses (IV)	2827.25	2787.48	2660.23	8062.87	7476.17	9905.82
V	Profit before tax (III - IV)	775.70	923.88	768.48	2478.89	2459.91	2987.09
VI	Tax Expense						
	(i) Current Tax	250.00	250.00	150.00	700.00	600.00	735.00
	(ii) Income Tax for previous years	0.00	0.00	0.00	-7.70	-7.21	-7.21
	(iii) Deferred Tax	-17.68	-12.74	-4.23	-38.73	-17.72	29.58
VII	Profit after tax for the period (V-VI)	543.38	686.62	622.71	1825.32	1884.84	2229.72
VIII	Other Comprehensive Income						
A	(i) Items that will not be reclassified to profit or loss	53.40	68.61	-15.39	55.99	93.24	140.57
	(ii) Income Tax relating to Items that will not be reclassified to profit or loss	-6.12	-7.81	1.78	-6.41	-10.59	-10.55
B	(i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
IX	Total Comprehensive Income for the period (VII + VIII)	590.66	747.42	609.10	1874.90	1967.49	2359.74
	Paid up Equity Share Capital (F.V. Rs.10/- each) *	456.57	458.94	458.94	456.57	458.94	458.94
X	Earnings Per Share (in Rs.) (F.V. Rs.10/-) Basic and Diluted #	11.84	14.96	13.57	39.77	41.07	48.58

Notes:

- The above statement of standalone unaudited financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 7th February 2023.
- The Company is dealing exclusively in Pharmaceuticals business segment, hence segment wise reporting is not applicable.
- * The Company has initiated buyback of its equity shares w.e.f. 13.12.2022, through stock exchange mechanism. The said buyback is currently in process.
- # EPS is calculated on the basis of Weighted Average of the number of shares as per IND-AS 33.
- The figures of the previous year/period have been regrouped/rearranged to render them comparable with the figures of the current period.

 By order of the Board
For Jenburkt Pharmaceuticals Ltd.


(Ashish U. Bhuta)
Chairman & Managing Director

 Place : Mumbai
Date : 7th Feb, 2023

Science hai toh Hope hai Hope hai toh Health hai Health hai toh Happiness hai

D.R.MEHTA & ASSOCIATES

(CHARTERED ACCOUNTANTS)

H-2, EVEREST BUILDING, 9TH FLOOR, TARDEO CIRCLE, MUMBAI - 400034

TEL: 23513758 / 23520330 FAX: 66607263, 9322508373

Email ID: info@drmehta.in, vikram@drmehta.in, ashok@drmehta.in

Limited Review Report on Unaudited Quarterly Standalone Financial Results of Jenburkt Pharmaceuticals Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015

To the Board of Directors of

Jenburkt Pharmaceuticals Limited

We have reviewed the accompanying statement of unaudited standalone financial results of JENBURKT PHARMACEUTICALS LTD for the quarter ended 31st December 2022 ('the statement').

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

For D.R.Mehta & Associates,
Chartered Accountants
(Firm Reg. No. 106207W)



Partner

Vikram Mehta

(Membership No. 047347)

UDIN: 23047347BGSMOY7072

Place: Mumbai

Date: 7th February 2023

